secwatch.observer — SEC 8-K summary
======================================

Issuer:     LeonaBio, Inc. (LONA)
CIK:        0001620463
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0000950170-24-060452
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Athira Pharma Q1 2024 net loss $26.3M ($0.69/share); cash $122.1M; LIFT-AD data H2 2024
--------------------------------------------------------------------------------

- Net loss of $26.3M ($0.69/share) vs $27.8M ($0.73/share) in Q1 2023; operating cash burn $25.8M.
- Cash and investments $122.1M as of March 31, 2024, down from $147.4M at year-end 2023.
- LIFT-AD Phase 2/3 topline data for fosgonimeton in Alzheimer's expected H2 2024; enrollment complete.
- IND submitted for ATH-1105 (ALS); first-in-human study expected to start Q2 2024.
- Appointed Javier San Martin, M.D. as Chief Medical Officer in April 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1620463/000095017024060452/0000950170-24-060452-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1620463/000095017024060452/atha-20240515.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-060452

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer